MPXOF (MPX International) Debt-to-Equity: 3.64 (As of Mar. 2022)


What is MPX International Debt-to-Equity?

MPX International MPXOF -99.00% Debt-to-Equity is 3.64 as of Mar. 2022.

MPX International's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $6.55 Mil. MPX International's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2022 was $13.41 Mil. MPX International's Total Stockholders Equity for the quarter that ended in Mar. 2022 was $5.48 Mil. MPX International's debt to equity for the quarter that ended in Mar. 2022 was 3.64.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

The historical rank and industry rank for MPX International's Debt-to-Equity or its related term are showing as below:

MPXOF's Debt-to-Equity is not ranked *
in the Drug Manufacturers industry.
Industry Median: 0.27
* Ranked among companies with meaningful Debt-to-Equity only.

MPX International  (OTCPK:MPXOF) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.

Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.

MPX International Debt-to-Equity Related Terms

MPX International Debt-to-Equity Historical Data

* Premium members only.

The historical data trend for MPX International's Debt-to-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MPX International Debt-to-Equity Chart

MPX International Annual Data
Trend Sep18 Sep19 Sep20 Sep21
Debt-to-Equity
0.04 0.03 0.32 1.07

MPX International Quarterly Data
Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22
Debt-to-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.59 0.59 1.07 1.44 3.64

MPXOF vs ZTS, CTLT, VTRS: Debt-to-Equity Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, MPX International's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MPX International Debt-to-Equity vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MPX International's Debt-to-Equity distribution charts can be found below:

* The bar in red indicates where MPX International's Debt-to-Equity falls into.


MPX International Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

MPX International's Debt to Equity Ratio for the fiscal year that ended in Sep. 2021 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(5.69 + 9.103) / 13.793
=1.07

MPX International's Debt to Equity Ratio for the quarter that ended in Mar. 2022 is calculated as

Debt to Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(6.551 + 13.41) / 5.478
=3.64

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Debt-to-Equity →
What does a Debt-to-Equity of 3.64 mean?
MPX International (MPXOF) has a Debt-to-Equity of 3.64 as of Mar. 2022. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MPX International and its competitors.
Is MPX International's Debt-to-Equity too high?
MPX International's current Debt-to-Equity is 3.64. The Drug Manufacturers industry median Debt-to-Equity is 0.27. MPX International's value of 3.64 is 1248.1% above this industry median.
How does MPX International's Debt-to-Equity compare to ZTS and CTLT?
MPX International's Debt-to-Equity of 3.64 can be compared against companies in the Drug Manufacturers industry. The industry median Debt-to-Equity is 0.27. MPX International's value of 3.64 is 1248.1% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 810 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. MPX International's current Debt-to-Equity of 3.64 is 1248.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on MPX International and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. MPX International's current Debt-to-Equity is 3.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MPX International stock overvalued right now?
MPX International (MPXOF) has a current Debt-to-Equity of 3.64. The current Debt-to-Equity is 3.64 and 1248.1% above the Drug Manufacturers industry median of 0.27. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For MPX International (MPXOF), the current Debt-to-Equity is 3.64 as of Mar. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

MPX International Business Description

Address 5255 Yonge Street, Suite 701, Toronto, ON, CAN, M2N 6P4
MPX International Corp is a diversified cannabis company focused on developing and operating assets across the global medical and adult use and engaged in cultivating, manufacturing and marketing products that include cannabinoids as their primary active ingredient. The firm is organized into three segments: Canada, Europe/Africa, and Asia-Pacific. The Canada operating segment's principal business activities consist of production and sale of cannabis, video learning and engagement, patient counselling and referral services. The Europe/Africa operating segment's consist of the production and sale of cannabis and hemp-related products. The Asia-Pacific consist of the production and sale of cannabis. The majority of the revenue is generated in Canada.